Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€15.73

€15.73

-5.690%
-0.945
-5.690%
€40.00

€40.00

 
01.12.21 / Tradegate WKN: A1W7D4 / Name: Aurinia Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
28.11.21
-7.47%
buy
€40.00
27.10.21
-39.17%
buy
15.07.21
62.06%
buy
Best running prediction
-
15.07.21
62.06%
buy
Your prediction

Aurinia Pharmaceuticals Inc. Stock

Aurinia Pharmaceuticals Inc. took a tumble today and lost -€0.945 (-5.690%).
Our community is currently high on Aurinia Pharmaceuticals Inc. with 3 Buy predictions and 0 Sell predictions.
Based on the current price of €15.73 the target price of €40.00 shows a potential of 154.291% for Aurinia Pharmaceuticals Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Aurinia Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Aurinia Pharmaceuticals Inc. in the next few years

Pros
3
Could be worthwhile Investment >10% per year
Cons
0
-

Performance of Aurinia Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Aurinia Pharmaceuticals Inc. -5.690% -10.676% -43.821% 29.465% 38.468% 192.924% -
Promis Neurosciences Inc 2.730% -16.279% -29.134% 51.771% 70.778% - -
InMed Pharmaceuticals Inc. -7.230% -7.006% 8.148% -52.597% -44.275% - -
Spectral Medical Inc -8.720% 8.276% -15.591% -32.328% -41.852% 0.641% 23.622%

Comments

Buy Aurinia Pharmaceuticals Inc.
Show more

Sell Aurinia Pharmaceuticals Inc.
Show more

Sell Aurinia Pharmaceuticals Inc.
Show more

Other discussions about Aurinia Pharmaceuticals Inc. Stock

Trading Aurinia Pharmaceuticals Inc.

Trading Aurinia Pharmaceuticals Inc.

New thread Forum

News

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November

Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated